<i>HER2</i> gene copy number and breast cancer‐specific survival

Biserni, Giovanni Battista; Engstrøm, Monica Jernberg; Bofin, Anna M.

doi:10.1111/his.13010

Cited by 13 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, data on the prognostic impact of double-equivocal HER2 status remain controversial. 26 – 28 Our results on the relatively high frequency of TP53 mutations may support the contention that these cases constitute an aggressive subgroup of ER-positive carcinomas. This is in line with the risk-based stratification of the cohort provided by Prosigna analysis, which demonstrated high RORs, even within the subgroup of node-negative G2 carcinomas with tumor size <2 cm.…”

Section: Discussionsupporting

confidence: 75%

The Dilemma of HER2 Double-equivocal Breast Carcinomas

Marchiò

Dell’Orto

Annaratone³

et al. 2018

American Journal of Surgical Pathology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 75%

The Dilemma of HER2 Double-equivocal Breast Carcinomas

Marchiò

Dell’Orto

Annaratone³

et al. 2018

American Journal of Surgical Pathology

View full text Add to dashboard Cite

show abstract

“…HER2-positive breast cancer is a distinctive subtype that is associated with aggressive behavior and has a poorer outcome compared with HER2-negative disease [2]. Over the past 10 years, the addition of trastuzumab to chemotherapy has dramatically changed the clinical outcomes of patients with HER2-positive breast cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Clinical studies have shown that the HER2 gene is overexpressed in 15% of breast cancers, which is associated with increased tumor aggressiveness and thought to be associated with poor prognosis [2].…”

Section: Introductionmentioning

confidence: 99%

Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis

Wang

Sun

et al. 2018

Oncol Res Treat

View full text Add to dashboard Cite

Aim: The purposes of our study were to compare the clinical outcomes of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) patients with or without trastuzumab treatment and HER2-negative patients, and to explore factors that might predict the survival benefit associated with trastuzumab treatment in HER2-positive breast cancer. Patients and Methods: A total of 421 patients with mBC were analyzed in this retrospective study. All patients had first-line chemotherapy with or without trastuzumab. They were classified into 3 groups according to their HER2 status and trastuzumab treatment: HER2-positive mBC patients with or without trastuzumab treatment and HER2-negative patents. Results: Trastuzumab administration in HER2-positive mBC patients significantly prolonged overall survival (33 vs. 26 months; P = 0.003) and led to a 49.8% reduction in death risk. In the subgroup analysis, HER2-positive patients with hormone receptor (HR)-negative status (29 vs. 17 months; P = 0.000) or visceral metastasis (30 vs. 21 months; P = 0.000) had more survival benefit when treated with trastuzumab. Conclusions: Trastuzumab administration significantly improved the overall survival in HER2-positive mBC patients, who gained a prognosis comparable to that of patients with HER2-negative disease. HR status and metastasis site might be important surrogate makers that predict survival benefit from trastuzumab-based treatment.

show abstract

“…Both the HER2 /CEP17 ratio and the HER2 copy number were measured, and no significant effect on prognosis or benefit from trastuzumab was observed with different levels of HER2 amplification. In contrast, it was recently reported that there was an increased risk of death from BC in the first 5 years after diagnosis in women with HER2 copy numbers of ≥6, as well as of ≥4.0 and <6.0, irrespective of HER2 /CEP17 ratio . The conflicting clinical data suggest that the variability of the HER2 /CEP17 ratio and the HER2 copy number, depending on the number of cells counted, may determine the accuracy of the final result.…”

Section: Discussionmentioning

confidence: 99%